Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019”
1. Introduction
2. The Present Special Issue on “Tuberculosis Drug Discovery and Development 2019”
3. Conclusions
Funding
Conflicts of Interest
References
- WHO. Global Tuberculosis Report 2019; WHO: Geneva, Switzerland, 2019. [Google Scholar]
- du Bruyn, E.; Peton, N.; Esmail, H.; Howlett, P.J.; Coussens, A.K.; Wilkinson, R.J. Recent progress in understanding immune activation in the pathogenesis in HIV-tuberculosis co-infection. Curr. Opin. HIV AIDS 2018, 13, 455–461. [Google Scholar] [CrossRef] [PubMed]
- Ferlita, S.; Yegiazaryan, A.; Noori, N.; Lal, G.; Nguyen, T.; To, K.; Venketaraman, V. Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis. J. Clin. Med. 2019, 8, 2219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- WHO. The End-TB Strategy; WHO: Geneva, Switzerland, 2014. [Google Scholar]
- Mabhula, A.; Singh, V. Drug-resistance in Mycobacterium tuberculosis: Where we stand. MedChemComm 2019, 10, 1342–1360. [Google Scholar] [CrossRef] [PubMed]
- Pontali, E.; Raviglione, M.C.; Migliori, G.B. Regimens to treat multidrug-resistant tuberculosis: Past, present and future perspectives. Eur. Respir. Rev. Off. J. Eur. Respir. Soc. 2019, 28. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bandodkar, B.; Shandil, R.; Bhat, J.; Balganesh, T. Two Decades of TB Drug Discovery Efforts—What Have We Learned? Appl. Sci. 2020, 10, 5704. [Google Scholar] [CrossRef]
- Lienhardt, C.; Raviglione, M. TB Elimination Requires Discovery and Development of Transformational Agents. Appl. Sci. 2020, 10, 2605. [Google Scholar] [CrossRef] [Green Version]
- Iacobino, A.; Fattorini, L.; Giannoni, F. Drug-Resistant Tuberculosis 2020: Where We Stand. Appl. Sci. 2020, 10, 2153. [Google Scholar] [CrossRef] [Green Version]
- Mazzarello, P. A Physical Cure for Tuberculosis: Carlo Forlanini and the Invention of Therapeutic Pneumothorax. Appl. Sci. 2020, 10, 3138. [Google Scholar] [CrossRef]
- Vilchèze, C. Mycobacterial Cell Wall: A Source of Successful Targets for Old and New Drugs. Appl. Sci. 2020, 10, 2278. [Google Scholar] [CrossRef] [Green Version]
- Degiacomi, G.; Belardinelli, J.; Pasca, M.; De Rossi, E.; Riccardi, G.; Chiarelli, L. Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3. Appl. Sci. 2020, 10, 623. [Google Scholar] [CrossRef] [Green Version]
- Foo, C.; Pethe, K.; Lupien, A. Oxidative Phosphorylation—An Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis. Appl. Sci. 2020, 10, 2339. [Google Scholar] [CrossRef] [Green Version]
- Gries, R.; Sala, C.; Rybniker, J. Host-Directed Therapies and Anti-Virulence Compounds to Address Anti-Microbial Resistant Tuberculosis Infection. Appl. Sci. 2020, 10, 2688. [Google Scholar] [CrossRef] [Green Version]
- Visca, D.; Tiberi, S.; Centis, R.; D’Ambrosio, L.; Pontali, E.; Mariani, A.; Zampogna, E.; van den Boom, M.; Spanevello, A.; Migliori, G. Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. Appl. Sci. 2020, 10, 2734. [Google Scholar] [CrossRef]
- Makarov, V.; Mikušová, K. Development of Macozinone for TB treatment: An Update. Appl. Sci. 2020, 10, 2269. [Google Scholar] [CrossRef] [Green Version]
- Cho, Y.; Jang, J. Development of Delpazolid for the Treatment of Tuberculosis. Appl. Sci. 2020, 10, 2211. [Google Scholar] [CrossRef] [Green Version]
- van Wijk, R.; Ayoun Alsoud, R.; Lennernäs, H.; Simonsson, U. Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations. Appl. Sci. 2020, 10, 2376. [Google Scholar] [CrossRef] [Green Version]
- Bruch, E.; Petrella, S.; Bellinzoni, M. Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead. Appl. Sci. 2020, 10, 4248. [Google Scholar] [CrossRef]
- Goff, A.; Cantillon, D.; Muraro Wildner, L.; Waddell, S. Multi-Omics Technologies Applied to Tuberculosis Drug Discovery. Appl. Sci. 2020, 10, 4629. [Google Scholar] [CrossRef]
- Rappuoli, R. Drugs and Vaccines Will Be Necessary to Control Tuberculosis. Appl. Sci. 2020, 10, 4026. [Google Scholar] [CrossRef]
- Martin, C.; Aguilo, N.; Marinova, D.; Gonzalo-Asensio, J. Update on TB Vaccine Pipeline. Appl. Sci. 2020, 10, 2632. [Google Scholar] [CrossRef] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sala, C.; Chiarelli, L.R.; Riccardi, G. Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019”. Appl. Sci. 2020, 10, 6069. https://doi.org/10.3390/app10176069
Sala C, Chiarelli LR, Riccardi G. Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019”. Applied Sciences. 2020; 10(17):6069. https://doi.org/10.3390/app10176069
Chicago/Turabian StyleSala, Claudia, Laurent Roberto Chiarelli, and Giovanna Riccardi. 2020. "Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019”" Applied Sciences 10, no. 17: 6069. https://doi.org/10.3390/app10176069
APA StyleSala, C., Chiarelli, L. R., & Riccardi, G. (2020). Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019”. Applied Sciences, 10(17), 6069. https://doi.org/10.3390/app10176069